Real-World Evidence Insights - 19.12.24

Bringing Real-World Evidence to the Forefront of Clinical Innovation

Author

Liam Ball
December 19, 2024 • Estimated Reading Time: 5 minutes

Innovation Spotlight

ICAREdata: Transforming Real-World Evidence in Oncology

The ICAREdata project, recently highlighted in JAMIA Open (2024), has set a new benchmark in leveraging electronic health records (EHRs) for oncology research. By using the minimal Common Oncology Data Elements (mCODE), the initiative demonstrated how structured, standardized data can be collected and transmitted across multiple clinical sites and trials.

This breakthrough has major implications for real-world evidence (RWE):

  • Enhanced Clinical Trials: Structured RWD enables more efficient trial designs and better outcome measurement.

  • Improved Care Delivery: High-quality data from real-world settings can guide better treatment strategies.

  • Scalability: ICAREdata's success offers a roadmap for deploying similar projects across other therapeutic areas.

Despite challenges - ranging from technical interoperability to clinician engagement - the project’s success reinforces the potential of EHRs to become a cornerstone of RWE generation. For clinical partnerships, this is an exciting opportunity to invest in systems and collaborations that unlock the full power of EHR data.

RWE Insights from Recent Research

TAVR vs. SAVR: Real-World Evidence on Long-Term Outcomes

Scarpanti et al. (2024) used RWD to compare 5-year mortality rates between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR). The findings emphasize the importance of RWE in assessing treatment effectiveness outside controlled trial settings, giving healthcare leaders valuable tools for decision-making.

AI-Driven Clinical Trial Optimisation

Anuyah et al. (2024) reveal how deep learning and predictive modelling are revolutionising trial design, from patient stratification to adverse event prediction. These advancements highlight AI’s role in generating RWE that drives patient-centred care and accelerates clinical trial timelines.

Genomic Insights into Infections

Valik et al. (2024) underscore the value of genomic RWE in predicting outcomes for Pseudomonas aeruginosa bloodstream infections. By linking genomic virulence markers to severe outcomes, this research sets the stage for precision treatments driven by real-world genomic data.

Genetic Profiling in Pancreatic Cancer

So et al. (2024) demonstrate how comprehensive genomic profiling (CGP) can improve overall survival in advanced pancreatic cancer patients. This study reinforces the role of RWE in guiding precision medicine, offering actionable insights for clinical partnerships.

Key Takeaways

  1. Standardisation is Key: Projects like ICAREdata show that structured data collection drives impactful research. Investing in standardised frameworks like mCODE is essential for scaling RWE initiatives.

  2. Technology as a Catalyst: AI and genomics are transforming how RWE is collected, analysed, and applied. Partnerships with tech-driven solutions can accelerate innovation.

  3. Collaborate to Scale: Multi-site initiatives like ICAREdata highlight the power of collaboration in generating meaningful RWE. Building strategic partnerships will be crucial to realising the potential of real-world data.

Stay ahead by embracing innovations that make RWE a driver of clinical transformation.

Health Spotlight’s Research Insights is a Contentive publication in the Healthcare division